Olivier Ossipoff
Chairman @ Xerys
Paris, France
Olivier Ossipoff is a venture - series unknown investor at Xerys in Paris focused on Health Care and Biotechnology. Olivier Ossipoff - Chairman @ Xerys
- Total investments:
- 7
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Olivier Ossipoff invests in
Stages Olivier Ossipoff invests in
Countries Olivier Ossipoff invests in
Investment Focus
Industry
- Health Care 2 (29%)
- Biotechnology 2 (29%)
- Medical 1 (14%)
- Biopharma 1 (14%)
- Recycling 1 (14%)
Stage
- Venture - Series Unknown 3 (43%)
- Series B 1 (14%)
- Funding Round 1 (14%)
Country
- France 3 (43%)
- United States 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Advanced BioDesign, as an immunotechnology specialist, provides a tailored and high value solution to their research. This new company keeps his main research activity in Oncology, Infectious Diseases and in Neuroscience Fields. One of its major strengths is to follow its customers during the development of their own kits, from the feasibility tothe technology transfer. | $15.6M / Venture - Series Unknown / Feb 02, 2023 | |
|
|
Biolog-id is a designer-integrator which has specialized for the last thirty years in electronic identification and mobile data processing. It develops complete solutions for identification and traceability in life science.The mastering of the communication protocols, including those linked to the RFID (Radio Frequency Identification), and thecapacity to develop interface programs, allowing the company to answer to any specific demands is the solution in whichever environment is worked on. About seventy international patents protect the discoveries developed by Biolog-id. | $25M / Venture - Series Unknown / May 05, 2022 | |
|
|
Skytech provides innovative solutions and unique recovery services for plastics for the benefit of manufacturers. Skytech gives plastics a second life. It has developed TRIBLAST, an innovative and patented process for recycling polymers based on triboelectricity. It contributes to the development of the circular economy. | $6.1M / Venture - Series Unknown / Jan 13, 2021 | |
|
|
Advanced BioDesign, as an immunotechnology specialist, provides a tailored and high value solution to their research. This new company keeps his main research activity in Oncology, Infectious Diseases and in Neuroscience Fields. One of its major strengths is to follow its customers during the development of their own kits, from the feasibility tothe technology transfer. | $9.8M / Venture - Series Unknown / Feb 25, 2020 | |
|
|
Biolog-id is a designer-integrator which has specialized for the last thirty years in electronic identification and mobile data processing. It develops complete solutions for identification and traceability in life science.The mastering of the communication protocols, including those linked to the RFID (Radio Frequency Identification), and thecapacity to develop interface programs, allowing the company to answer to any specific demands is the solution in whichever environment is worked on. About seventy international patents protect the discoveries developed by Biolog-id. | $32.9M / Nov 19, 2019 | |
|
|
AlzProtect is a biopharmaceutical company developing drug candidates from discovery to clinical trials for the treatment of neurodegenerative diseases including Alzheimer's disease (AD) and orphan tauopathies such as Progressive Supranuclear Palsy (PSP). | $15.4M / Series B / Jan 22, 2018 | |
|
|
Biolog-id is a designer-integrator which has specialized for the last thirty years in electronic identification and mobile data processing. It develops complete solutions for identification and traceability in life science.The mastering of the communication protocols, including those linked to the RFID (Radio Frequency Identification), and thecapacity to develop interface programs, allowing the company to answer to any specific demands is the solution in whichever environment is worked on. About seventy international patents protect the discoveries developed by Biolog-id. |
About Xerys
Xery is a portfolio management Company specializing in Venture Capital - Biotech, Medtech, Cleantech, Technology
Xerys Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jacques Simonnet
Chairman of the supervisory board
|
|||
|
Olivier Ossipoff
Chairman
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Olivier Ossipoff invest in?
Olivier Ossipoff invests primarily in Health Care, Biotechnology and Medical startups, most often at Venture - Series Unknown and Series B stage. Most of the 7 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Olivier Ossipoff last invest?
The most recent investment recorded for Olivier Ossipoff closed in Feb 2023. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!